Takeda Pharmaceutical analyst ratings
Takeda Pharmaceutical analyst ratings
While ratings are subjective and will change, the latest Takeda Pharmaceutical (TAK) rating was a upgraded with a price target of $21.00 to $24.00. The current price Takeda Pharmaceutical (TAK) is trading at is $14.41, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/19/2022 | 66.61% | Cowen & Co. | $21 → $24 | Upgrades | Market Perform → Outperform |
| 10/07/2021 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
| 03/11/2020 | 108.26% | JP Morgan | $31 → $30 | Maintains | Overweight |
| 11/01/2019 | 35.37% | Cowen & Co. | → $19.5 | Initiates Coverage On | → Market Perform |
| 09/24/2019 | — | Jefferies | Initiates Coverage On | → Buy | |
| 03/19/2019 | — | Goldman Sachs | Reinstates | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 7 月 19 日 | 66.61% | Cowen & Co. | 21 美元 → 24 美元 | 升級 | 市場表現 → 跑贏大盤 |
| 2021 年 7 月 10 日 | — | 摩根士丹利 | 降級 | 超重 → 重量相等 | |
| 03/11/2020 | 108.26% | 摩根大通 | 31 美元 → 30 美元 | 維護 | 超重 |
| 11/01/2019 | 35.37% | Cowen & Co. | → 19.5 美元 | 啓動覆蓋範圍開啓 | → 市場表現 |
| 2019 年 9 月 24 日 | — | 傑富瑞集團 | 啓動覆蓋範圍開啓 | → 購買 | |
| 03/19/2019 | — | 高盛 | 恢復 | → 購買 |
Takeda Pharmaceutical Questions & Answers
武田製藥問答
The latest price target for Takeda Pharmaceutical (NYSE: TAK) was reported by Cowen & Co. on July 19, 2022. The analyst firm set a price target for $24.00 expecting TAK to rise to within 12 months (a possible 66.61% upside). 2 analyst firms have reported ratings in the last year.
Cowen & Co. 於2022年7月19日公佈了武田製藥（紐約證券交易所代碼：TAK）的最新目標股價。該分析公司將目標股價定爲24.00美元，預計TAK將在12個月內升至12個月內（可能上漲66.61％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for Takeda Pharmaceutical (NYSE: TAK) was provided by Cowen & Co., and Takeda Pharmaceutical upgraded their outperform rating.
武田製藥（紐約證券交易所代碼：TAK）的最新分析師評級由Cowen & Co. 提供，武田藥業上調了跑贏大盤的評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Takeda Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Takeda Pharmaceutical was filed on July 19, 2022 so you should expect the next rating to be made available sometime around July 19, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與武田製藥的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。武田製藥的最新評級是在2022年7月19日發佈的，因此您應該預計下一個評級將在2023年7月19日左右公佈。
While ratings are subjective and will change, the latest Takeda Pharmaceutical (TAK) rating was a upgraded with a price target of $21.00 to $24.00. The current price Takeda Pharmaceutical (TAK) is trading at is $14.41, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但武田製藥（TAK）的最新評級已上調，目標股價爲21.00美元，至24.00美元。武田製藥（TAK）目前的交易價格爲14.41美元，超出了分析師的預期區間。
